Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: The ludwigshafen risk and cardiovascular health study

Circulation

Volumn 121, Issue 3, 2010, Pages 366-374

  Ritsch, Andreas ^a   Scharnagl, Hubert ^b   Eller, Philipp ^a   Tancevski, Ivan ^a   Duwensee, Kristina ^a   Demetz, Egon ^a   Sandhofer, Anton ^a   Boehm, Bernhard O ^c   Winkelmann, Bernhard R ^d   Patsch, Josef R ^a   März, Winfried ^b,e,f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY HOSPITAL ULM   (Germany)

^d Cardiology Group   (Germany)

^e SYNLAB ACADEMY   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Atherosclerosis; Coronary disease; Lipoproteins; Mortality; Risk factors

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; INTERLEUKIN 6;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORRELATION ANALYSIS; DIABETES MELLITUS; FEMALE; GERMANY; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEINS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; LIPOPROTEINS; MALE; MIDDLE AGED; MORBIDITY; PROPORTIONAL HAZARDS MODELS; REFERRAL AND CONSULTATION; RISK FACTORS;

EID: 76649140069     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.109.875013     Document Type: Article

References (21)

1. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34: 1255-1274.
2. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov. 2008;7:143-155.
3. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cho-lesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
4. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, Revkin JH, Grobbee DE, Riley WA, Shear CL, Duggan WT, Bots ML. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630.
5. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
6. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356: 1304-1316.
7. Olsson AG. Is high HDL cholesterol always good? Ann Med. 2008;41: 11-18.
8. Rader DJ. Illuminating HDL: is it still a viable therapeutic target? N Engl J Med. 2007;357:2180-2183.
9. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J. Rationale and design of the LURIC study: a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001;2:S1-S73.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(suppl 1):S43-S48.
11. Ritsch A, Auer B, Foger B, Schwarz S, Patsch JR. Polyclonal antibody-based immunoradiometric assay for quantification of cho-lesteryl ester transfer protein. J Lipid Res. 1993;34:673-679.
12. Ritsch A, Ebenbichler C, Naschberger E, Schgoer W, Stanzl U, Dietrich H, Heinrich PC, Saito K, Patsch JR. Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clin Chem Lab Med. 2004;42:247-255.
13. Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008;299:2777-2788.
14. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol. 2008;51: 2199-2211.
15. Föger B, Ritsch A, Doblinger A, Wessels H, Patsch JR. Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1996;16:1430-1436.
16. Rye KA, Barter PJ. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol. 2008;28:1890-1891.
17. Cai L, Ji A, de Beer FC, Tannock LR, van der Westhuyzen DR. SR-BI protects against endotoxemia in mice through its roles in glucocorticoid production and hepatic clearance. J Clin Invest. 2008;118:364-375.
18. Cazita PM, Barbeiro DF, Moretti AI, Quintao EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. Shock. 2008;30:590-595.
19. Marschang P, Sandhofer A, Ritsch A, Fiser I, Kvas E, Patsch JR. Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. J Intern Med. 2006;260:151-159.
20. Ritsch A, Patsch JR. Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Curr Opin Lipidol. 2003;14:173-179.
21. Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest. 1996;97:2917-2923.